Membrane Attack Complex Pores for Therapeutic Cargo Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic macromolecules like siRNAs and gene-editing components into cells are inefficient due to degradation, immune surveillance, and poor membrane penetration, limiting their effectiveness in clinical applications, especially for cancer and age-related macular degeneration.
Innovation Solution
Formation of a membrane attack complex (MAC) using purified human complement components C5b-6, C7, C8, and C9 to create pores in cell membranes, facilitating the uptake of therapeutic cargo, including nucleic acids and polypeptides, into cells, thereby enabling the delivery of therapeutic agents that cannot cross the cell membrane in native form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic macromolecules are delivered into target cells, then treatment effectiveness is improved, but delivery efficiency is poor due to membrane impermeability
Solution Approach 1:
The patent uses membrane attack complex (MAC) as an intermediary to facilitate the delivery of therapeutic macromolecules across the cell membrane. MAC forms transient pores in the membrane, allowing macromolecules to enter cells without requiring them to be inherently membrane-permeable, thus resolving the contradiction between treatment effectiveness and delivery efficiency
Solution Approach 2:
The patent changes the physical state of the cell membrane by inducing transient pore formation through MAC assembly. This temporary alteration in membrane permeability parameters enables macromolecule entry that would otherwise be blocked, improving delivery efficiency while maintaining treatment effectiveness
2Reliability
If high doses of therapeutic agents are administered, then treatment effectiveness is improved, but toxicity increases
Solution Approach 1:
MAC serves as a mediator that enables efficient macromolecule delivery at lower concentrations. By improving the delivery mechanism rather than increasing the dose, the patent achieves treatment effectiveness while avoiding the toxicity associated with high-dose administration
3Stability of the object's composition
If siRNAs are shielded from degradation, then stability is improved, but delivery complexity increases
Solution Approach 1:
The patent uses MAC as a simple biological mediator that naturally protects and delivers macromolecules. This approach maintains siRNA stability through a biologically native mechanism rather than complex synthetic shielding approaches, reducing delivery system complexity while preserving stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MAC system allows for the safe and efficient delivery of therapeutic macromolecules, reducing the need for high, potentially toxic doses and enabling effective treatment of cancers and age-related macular degeneration by targeting specific genes and pathways, such as cyclin D1 and VEGF/Ang-2, with lower toxic formulations.
Implementation Method 1
contacting the cell with a purified human C5b-6 and the therapeutic cargo; and contacting the cell with a purified C7, C8, and C9, thereby forming a membrane attack complex (MAC) in the membrane of the cell, facilitating entry of the therapeutic cargo into the cell
Data Source
AI summary
The invention features methods for introducing a therapeutic cargo into a cell of a subject. Such methods include the steps of (a) contacting the cell with a purified human CSb-6 and the therapeutic cargo; and (b) contacting the cell with a purified C7, C8, and C9, thereby forming a membrane attack complex (MAC) in the membrane of the cell, facilitating entry of the therapeutic cargo into the cell. Still another method involves treating neovascularization in an eye of a subject, the method comprising the steps of (a) contacting choroidal blood vessels of the eye with a purified human CSb-6 and the therapeutic cargo; and (b) contacting the choroidal blood vessels with a purified C7, C8, and C9, thereby forming MACS in cells of the choroidal blood vessels, facilitating entry of the therapeutic cargo into the cells of the choroidal blood vessels for treating neovascularization.